性健康是子宫内膜异位症女性的主要关注点,然而,只有少数对照研究用经过验证的仪器检查了这一点。激素治疗对子宫内膜异位症性功能的影响也是一个被低估的话题。这项研究的目的是通过一种特定的工具来调查子宫内膜异位症患者的性功能,以更好地评估他们的性功能(包括不同的领域)。以及激素治疗或手术对这些参数的影响。
■观测,横截面,多中心研究是在一组(n=194)性活跃的人中进行的,25-45岁的女性,手术或超声诊断为子宫内膜异位症,转诊到Careggi大学医院或NegrardiValpolicella的子宫内膜异位症中心。通过女性性功能指数(FSFI)评估性功能,评估欲望的领域,唤醒,润滑,性高潮,满意和痛苦。根据子宫内膜异位症患者接受的治疗,将FSFI评分与对照组(n=58)进行比较。
■卵巢子宫内膜异位症有50例(25.8%),65例(33.5%)和79例(40.7%)均为深部浸润型子宫内膜异位症。102例(52.6%)同时存在子宫腺肌病。子宫内膜异位症女性FSFI平均总评分为18.3[4.2-25.8](<26.55),表明所有患者的女性性功能障碍(FSD)。在多变量分析中,在调整了混杂因素(BMI和激素治疗)后,在所有FSFI中,子宫内膜异位症女性的评分均显著低于对照组(p<0.001).激素治疗下的子宫内膜异位症患者(n=124;64%),无论类型,在所有FSFI分量表和总分中得分明显较低,即使在调整了混杂因素年龄之后,BMI和手术史。
■子宫内膜异位症患者有FSD的风险,不仅包括性交困难,而是性功能的所有领域。激素治疗不会导致性症状的改善。
UNASSIGNED: Sexual health is a major concern in women with endometriosis, however only a few controlled studies have examined this with validated instruments. The effect of hormonal treatments on sexual function in endometriosis is also an underrated topic. The aim of this
study was to investigate sexual function of patients with endometriosis by a specific tool to better evaluate their sexual function (including different domains), and the influence of hormonal treatment or surgery on these parameters.
UNASSIGNED: An observational, cross-sectional, multicentre
study was conducted in a group (n=194) of sexually active, women aged 25-45 years old, with surgical or ultrasonographic diagnosis of endometriosis, referred to the Endometriosis Center of Careggi University Hospital or Negrar di Valpolicella. Sexual function was assessed by administering the Female Sexual Function Index (FSFI), which assesses the domains of desire, arousal, lubrication, orgasm, satisfaction and pain. FSFI scores were compared to those of a control group (n=58) and according to the treatment received by patients with endometriosis.
UNASSIGNED: Ovarian endometriosis was present in 50 patients (25.8%), deep infiltrating endometriosis in 65 patients (33.5%) and both in 79 patients (40.7%). Adenomyosis coexisted in 102 patients (52.6%). Women with endometriosis reported a mean total FSFI score of 18.3 [4.2-25.8] (< 26.55), indicating female sexual dysfunction (FSD) in all patients. At multivariate analysis, after adjusting for confounders (BMI and hormonal therapy), women with endometriosis presented significantly lower scores than controls in all the FSFI (p<0.001). Patients with endometriosis under hormonal treatments (n=124; 64%), regardless of the type, had significantly lower scores in all FSFI subscales and total score, even after adjusting for confounders-age, BMI and history of surgery.
UNASSIGNED: Patients with endometriosis are at risk for FSD, encompassing not only dyspareunia, but all domains of sexual function. Hormonal treatments do not result in improvement in sexual symptoms.